As the precursor of NAFLD, deleting AKT2, the downstream target of PTEN signal, can block the development of NASH and reduce the development of liver fibrosis, which also reduces the occurrence of NAFLD from another development process (23). Here, AKT2 is linked to metabolic dysfunction-associated steatotic liver disease.